Myocardial infarction or arterial thrombotic event within  months, heart failure of New York Heart Association class II or higher, uncontrolled angina, severe uncontrolled ventricular arrhythmia
Patient must not have significant cardiovascular disease, such as New York Heart Association cardiac disease (class II or greater), myocardial infarction within  months prior to initiation of treatment, unstable arrhythmias, or unstable angina given the higher risks associated with surgical resection
New York Heart Association congestive heart failure of grade II or above, unstable angina, myocardial infarction within the past  months, or serious cardiac arrhythmia associated with significant cardiovascular impairment within the past  months
Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke within  months of the first dose of study drug; or cardiac arrhythmia requiring medical treatment (including oral anticoagulation)
Uncontrolled or severe cardiovascular disease, including myocardial infarction or unstable angina within six months prior to study treatment, New York Heart Association (NYHA) Class II or greater congestive heart failure, serious arrhythmias requiring medication for treatment, clinically significant pericardial disease or cardiac amyloidosis.
For Parts F and H: Cardiac disease including myocardial infarction within  months, unstable angina, or New York Heart Association (NYHA) Grade II or greater functional impairment.
History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of , unstable angina or poorly controlled arrhythmia, or myocardial infarction within  months prior to randomization
History of symptomatic congestive heart failure ([CHF]; New York Heart Association [NYHA] Classes II-IV), ventricular arrhythmia requiring treatment, current unstable angina, or history of myocardial infarction within  months prior to study entry
Significant cardiovascular impairment within  months prior to the first dose of study drug; history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke, or cardiac arrhythmia associated with significant cardiovascular impairment
Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within the previous  months, unstable arrhythmias, or unstable angina.
Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within  months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
Uncontrolled or severe cardiovascular disease, including myocardial infarct or unstable angina within  months before study treatment, New York Heart Association Class II or greater congestive heart failure, serious arrhythmias requiring medication for treatment, clinically significant pericardial disease or cardiac amyloidosis.
History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of , unstable angina or poorly controlled arrhythmia as determined by the investigator; myocardial infarction within  months prior to registration
Patients with uncontrolled or severe cardiovascular disease, including myocardial infarct or unstable angina within  months prior to start of study treatment, New York Heart Association (NYHA) Class II or greater congestive heart failure, serious arrhythmias requiring medication for treatment, clinically significant pericardial disease, or cardiac amyloidosis may not be enrolled.
Clinically significant cardiac dysfunction defined as a history of >= New York Heart Association (NYHA) class II symptoms, angina, congestive heart failure, myocardial infarction, arrhythmias or cardiac dysfunction requiring treatment or discontinuation of chemotherapy
Myocardial infarction within  months before starting therapy, symptomatic congestive heart failure (New York Heart Association > class II), unstable angina, or unstable cardiac arrhythmia requiring medication.
Clinically significant (i.e., active) cardiovascular disease, for example cerebrovascular accidents =<  months prior to study enrollment, myocardial infarction =<  months prior to study enrollment, unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with protocol treatment.
Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) class II, unstable angina, myocardial infarction or stroke within  months of the first dose of study drug
Significant cardiovascular disease (i.e. New York Heart Association [NYHA] class  congestive heart failure; myocardial infarction within the past  months; unstable angina; coronary angioplasty with the past  months; uncontrolled atrial or ventricular cardiac arrhythmias)
Significant cardiovascular diseases (i.e., uncontrolled hypertension, unstable angina, history of infarction within the past  months prior to start of study treatment, congestive heart failure > New York Heart Association (NYHA) II, serious cardiac arrhythmia)
History of myocardial infarction or stroke within  months, congestive heart failure greater than New York Heart Associate (NYHA) class II, unstable angina pectoris, unexplained recurrent syncope, cardiac arrhythmia requiring treatment or family history of sudden death from cardiac-related causes
Significant cardiovascular disease (such as New York Heart Association class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within  months prior to initiation of study treatment, or unstable arrhythmia or unstable angina within  months prior to initiation of study treatment
Significant cardiovascular diseases within the past  months including uncontrolled congestive heart failure (> New York Heart Association [NYHA] class II), myocardial infarction, unstable angina, or uncontrolled arrhythmia
Has symptomatic congestive heart failure (New York Heart Association [NYHA] Classes II-IV), unstable angina, or cardiac arrhythmia requiring antiarrhythmic treatment.
Clinically significant (i.e. active) cardiovascular disease (e.g., myocardial infarction or arterial thromboembolic events =<  months prior to screening or severe or unstable angina, New York Heart Association (NYHA) class III or IV disease, grade II or greater congestive heart failure, or serious cardiac arrhythmia, or a corrected QT (QTc) interval >  msec)
Clinically significant cardiovascular disease with uncontrolled arrhythmia, New York Association class  or  congestive heart failure, history of myocardial infarction within  months, or prolonged corrected QT (QTc) >  msec
Cardiovascular disease or cerebrovascular disease, for example cerebrovascular accidents or myocardial infarction ?  months prior to study enrollment, unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled by medication or with the potential to interfere with protocol treatment;
History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of >= , unstable angina or poorly controlled arrhythmia as determined by the investigator; myocardial infarction within  months
Myocardial infarction within  months before starting therapy, symptomatic congestive heart failure (New York Heart Association > class II), unstable angina, or unstable cardiac arrhythmia requiring medication.
Clinically significant cardiovascular disease with uncontrolled arrhythmia, New York Association class  or  congestive heart failure, history of myocardial infarction within  months, or prolonged corrected QT (QTc) >  msec
Significant cardiovascular disease (i.e. New York Heart Association [NYHA] class  congestive heart failure; myocardial infarction with the past  months; unstable angina; coronary angioplasty with the past  months; uncontrolled atrial or ventricular cardiac arrhythmias)
Significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction within the past  months prior to start of study treatment, congestive heart failure > New York heart association ([NYHA] II, serious cardiac arrhythmia, pericardial effusion)
Patients with clinically significant cardiovascular disease; this includes:\r\n* Myocardial infarction or unstable angina <  months prior to registration\r\n* New York Heart Association (NYHA) grade II or greater congestive heart failure\r\n* Serious cardiac arrhythmia requiring medication; this does not include asymptomatic, atrial fibrillation with controlled ventricular rate
Myocardial infarction within  months before starting therapy, symptomatic congestive heart failure (New York Heart Association > class II), unstable angina, or unstable cardiac arrhythmia requiring medication
Significant history of uncontrolled cardiac disease including uncontrolled hypertension, unstable angina, cerebrovascular accidents or myocardial infarction within the last  months, and New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled by medication
Myocardial infarction within  months before starting therapy, symptomatic congestive heart failure (New York Heart Association > class II), unstable angina, or unstable cardiac arrhythmia requiring medication
Clinically significant heart disease (i.e., active), stroke or myocardial infarction within  months prior to enrollment, unstable angina pectoris, congestive heart failure of grade > II according to the New York Heart Association (NYHA), or cardiac arrhythmia requiring specific treatment during the study and that may interfere with the follow-up of the study treatment or poorly controlled by treatment
Has cardiovascular impairment, history of congestive heart failure greater than NYHA Class II, uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke within  months prior to the planned first dose of tazemetostat; or ventricular cardiac arrhythmia requiring medical treatment
Patients with history of serious cardiac events defined as: New York Heart Association class  or  heart failure, history of myocardial infarction, unstable angina, or cardiovascular accident (CVA) within  months of protocol registration; history of PR prolongation or atrioventricular (AV) block
Subject has a clinically significant cardiovascular disease including:\r\n* Uncontrolled hypertension\r\n* Myocardial infarction or unstable angina within  months prior to enrollment\r\n* New York Heart Association (NYHA) grade II or greater congestive heart failure
History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of , unstable angina or poorly controlled arrhythmia as determined by the investigator; myocardial infarction within  months prior to enrollment
Significant cardiovascular disease (i.e. New York Heart Association [NYHA] class  congestive heart failure; myocardial infarction with the past  months; unstable angina; coronary angioplasty with the past  months; uncontrolled atrial or ventricular cardiac arrhythmias)
Clinically significant (i.e., active) cardiovascular disease (e.g., cerebrovascular accident or myocardial infarction within  months prior to randomization), unstable angina, congestive heart failure (New York Heart Association class >= II) or serious cardiac arrhythmia that is uncontrolled by medication or may interfere with administration of study treatment
Patients with any of the following:\r\n* Uncontrolled angina at time of consent OR\r\n* > New York Heart Association (NYHA) class II congestive heart failure at time of consent OR\r\n* Myocardial infarction (MI) within  months prior to start of study treatment
Patients with clinically significant cardiovascular disease; this includes: uncontrolled hypertension (greater than /); myocardial infarction or unstable angina within  months prior to registration; New York Heart Association (NYHA) grade II or greater congestive heart failure; serious cardiac arrhythmia requiring medication; grade II or greater peripheral vascular disease; patients with clinically significant peripheral artery disease, e.g., those with claudication, within  months of first date of treatment on this study
Patient has clinically significant cardiovascular disease (e.g., significant cardiac conduction abnormalities, uncontrolled hypertension, myocardial infarction, cardiac arrhythmia or unstable angina, New York Heart Association Grade  or greater congestive heart failure, serious cardiac arrhythmia requiring medication, Grade  or greater peripheral vascular disease, and history of cerebrovascular accident (CVA)) within  months of enrollment.
Clinically significant (i.e. active) cardiovascular disease for example cerebro vascular accidents (<  months prior to enrolment), myocardial infarction (<  months prior to enrolment), unstable angina, New York Heart Association (NYHA) grade II or higher, congestive heart failure, serious cardiac arrhythmia requiring medication.
Have unstable angina, clinically significant cardiac arrhythmia, New York Heart Association Class  or  congestive heart failure, or prolonged QT interval corrected wave of greater than  ms.
Has significant cardiovascular impairment within  months of the first dose of study drug: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or cerebrovascular accident (CVA) stroke, or cardiac arrhythmia associated with hemodynamic instability, significant cardiovascular impairment, or a left ventricular ejection fraction (LVEF) below the institutional normal range as determined by multigated acquisition scan (MUGA) or echocardiogram
Patients who have significant cardiovascular diseases are not eligible; these are:\r\n* Uncontrolled hypertension\r\n* Unstable angina\r\n* History of infarction within the past  months prior to start of study treatment\r\n* Congestive heart failure > New York Heart Association (NYHA) II\r\n* Serious uncontrolled cardiac arrhythmia\r\n* Pericardial effusion
Clinically significant (i.e., active) cardiovascular disease (e.g., cerebrovascular accident or myocardial infarction [MI] within  months prior to randomization), unstable angina, congestive heart failure (CHF) (New York Heart Association [NYHA] class >= NII), or serious cardiac arrhythmia that is uncontrolled by medication or may interfere with administration of study treatment
Significant cardiovascular impairment (e.g., New York Heart Association congestive heart failure of grade II or above, unstable angina, myocardial infarction within the past  months, or serious cardiac arrhythmia)
Subjects with uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure (New York Heart Association [NYHA] class ), myocardial infarction within the past  months or serious uncontrolled cardiac arrhythmia are not eligible
Patients with uncontrolled hypertension (> /), unstable coronary disease evidenced by uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure (CHF) (> New York Heart Association [NYHA] class II), or myocardial infarction within  months of enrollment
Clinically evident congestive heart failure > class II of the New York Heart Association (NYHA) guidelines, unstable angina or myocardial infarction within the previous  months
Unstable cardiovascular function: \r\n* Electrocardiography (ECG) abnormalities requiring treatment, or   \r\n* Congestive heart failure (CHF) of New York Heart Association (NYHA) class >=  \r\n* Myocardial infarction (MI) within  months
History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of , unstable angina or poorly controlled arrhythmia; myocardial infarction within  months prior to enrollment
Patients must not have a history of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of , unstable angina or poorly controlled arrhythmia or myocardial infarction within  months prior to registration; if clinically indicated, echocardiogram or multigated acquisition (MUGA) must be performed and cardiac ejection fraction must be >= %
Significant cardiovascular impairment: congestive heart failure > class II according to the New York Heart Association (NYHA), unstable angina or myocardial infarction within  months of enrollment, or serious cardiac arrhythmia (> grade )
Subject has unstable angina, a significant cardiac arrhythmia, or New York Heart Association Class  or  congestive heart failure.
Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within  months prior to randomization, unstable arrhythmias, or unstable angina
Significant cardiovascular impairment: History of (a) congestive heart failure greater than New York Heart Association (NYHA) Class II, (b) unstable angina, (c) myocardial infarction, (d) stroke, or (e) cardiac arrhythmia associated with impairment within  months of the first dose of study drug.
Myocardial infarction, symptomatic congestive heart failure (New York Heart Association Classification > Class II), unstable angina, or serious uncontrolled cardiac arrhythmia within the last  months of Cycle  Day 
Has cardiovascular impairment, history of congestive heart failure greater than NYHA Class II uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke within  months prior to the planned first dose of tazemetostat; or ventricular cardiac arrhythmia requiring medical treatment
Significant cardiovascular disease, such as cardiac disease (New York Heart Association Class II or greater), myocardial infarction within the previous  months, unstable arrhythmias, or unstable angina
Has cardiovascular impairment, history of congestive heart failure greater than NYHA Class II, uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke within  months prior to the planned first dose of tazemetostat; or ventricular cardiac arrhythmia requiring medical treatment
Uncontrolled hypertension, unstable angina, New York Heart Association grade II or greater congestive heart failure, unstable symptomatic arrhythmia requiring medication, or clinically significant peripheral vascular disease (grade II or greater)
Significant cardiovascular disease, such as New York Heart Association cardiac disease (class II or greater), myocardial infarction, or cerebrovascular accident within  months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
Myocardial infarction, symptomatic congestive heart failure (New York Heart Association Classification > Class II), unstable angina, or serious uncontrolled cardiac arrhythmia within the last  months of CD
Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke within  months of the first dose of study drug; or cardiac arrhythmia requiring medical treatment (including oral anticoagulation).
Unstable angina, significant cardiac arrhythmia, or New York Heart Association (NYHA) class  or  congestive heart failure
Myocardial infarction within  months before starting therapy, symptomatic congestive heart failure (New York Heart Association > class II), unstable angina, or unstable cardiac arrhythmia requiring medication
Significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction within the past  months prior to start of study treatment, congestive heart failure > New York Heart Association [NYHA] II, serious cardiac arrhythmia, pericardial effusion)
? Grade  cardiac arrhythmia or uncontrolled atrial fib of any grade; Class  or  New York Heart Association congestive heart failure; history of severe/unstable angina, myocardial infarction or cerebrovascular accident within  months
Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within  months of the first dose of study drug, or cardiac arrhythmia requiring medical treatment at Screening
Uncontrolled or severe cardiovascular disease, including myocardial infarct or unstable angina within  months prior to study treatment, New York Heart Association (NYHA) Class II or greater congestive heart failure, serious arrhythmias requiring medication for treatment, clinically significant pericardial disease, or cardiac amyloidosis.
Unstable angina and/or congestive heart failure in the last  months, transmural myocardial infarction within the last  months, New York Heart Association grade II or higher congestive heart failure requiring hospitalization within  months prior to registration, evidence of recent (within  days of registration) myocardial infarction by electrocardiogram (EKG) (only required if clinically indicated), serious or inadequately controlled cardiac arrhythmia, significant vascular and peripheral vascular disease, evidence of bleeding diathesis or coagulopathy
History of significant cardiovascular disease, defined as: congestive heart failure greater than New York Heart Association (NYHA) class II according to the NYHA functional classification; unstable angina or myocardial infarction within  months of enrollment; or serious cardiac arrhythmia
Significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction within the past  months prior to start of study treatment, congestive heart failure > New York Heart Association [NYHA] II, serious cardiac arrhythmia, pericardial effusion)
No significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction within the past  months prior to start of study treatment, congestive heart failure > [New York Heart Association NYHA] II, serious cardiac arrhythmia, pericardial effusion)
Participant has significant active cardiac disease within the previous  months including unstable angina or angina requiring surgical or medical intervention, significant cardiac arrhythmia, or New York Heart Association (NYHA) class  or  congestive heart failure.
Subject has significant active cardiac disease within the previous  months including unstable angina or angina requiring surgical or medical intervention, significant cardiac arrhythmia, or New York Heart Association (NYHA) class  or  congestive heart failure.
Any known unstable angina, significant cardiac arrhythmia, or New York Heart Association (NYHA) class  or  congestive heart failure
Unstable angina and/or decompensated congestive heart failure in the last  months, transmural myocardial infarction within the last  months, New York Heart Association functional class II or higher congestive heart failure requiring hospitalization within  months prior to registration, serious or inadequately controlled cardiac arrhythmia, significant vascular and peripheral vascular disease, evidence of bleeding diathesis or coagulopathy
History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure, New York Heart Association (NYHA) functional classification of , unstable angina or poorly controlled arrhythmia; myocardial infarction within  month prior to the study entry
No patients with a history of cardiac disease: congestive heart failure > class II New York Heart Association (NYHA); active coronary artery disease (CAD) (myocardial infarction or unstable angina within  months prior to study entry)
Symptomatic congestive heart failure (New York Heart Association > class II), unstable angina, or unstable cardiac arrhythmia requiring medication (atrial fibrillation is permitted)
Uncontrolled or severe cardiovascular disease, including myocardial infarct or unstable angina within  months prior to study treatment, New York Heart Association (NYHA) Class II or greater congestive heart failure, serious arrhythmias requiring medication for treatment, clinically significant pericardial disease, or cardiac amyloidosis
History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of , unstable angina or poorly controlled arrhythmia; myocardial infarction within  months prior to study entry
Significant cardiovascular impairment within  months as defined as () congestive heart failure greater than New York Heart Association Class II, () unstable angina, () myocardial infarction; () stroke, () symptomatic cardiac arrhythmia
Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction, or stroke within  months of the first dose of study drug, or cardiac arrhythmia requiring medical treatment at Screening.
Clinically significant cardiovascular impairment (history of congestive heart failure greater or equal to New York Heart Association [NYHA] class II, unstable/active angina or myocardial infarction [MI] =<  months before day  of this study, or serious cardiac arrhythmia)
Clinically significant cardiovascular disease, defined as myocardial infarction (or unstable angina) within  months of registration, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac dysrhythmia refractory to medical management; however, treated and controlled or stable/not clinically significant cardiovascular disease is allowed per evaluation by cardiologist
Subject has a clinically significant cardiovascular disease including: uncontrolled hypertension; myocardial infarction or unstable angina within  months prior to registration; New York Heart Association (NYHA) Grade II or greater congestive heart failure
Significant cardiovascular impairment within  months of the first dose of study drug: history of congestive heart failure greater than New York Heart Association Class II, unstable angina, myocardial infarction, cerebrovascular accident, or cardiac arrhythmia associated with hemodynamic instability. The following is also excluded: left ventricular ejection fraction below the institutional normal range as determined by multiple-gated acquisition scan or echocardiogram
Significant cardiac disease as defined as: unstable angina, New York Heart Association (NYHA) grade II or greater, congestive heart failure, history of myocardial infarction within  months
Uncontrolled or severe concurrent medical condition including cardiovascular disease (e.g., myocardial infarct, unstable angina, New York Heart Association (NYHA) Class II or greater congestive heart failure, serious arrhythmias requiring medication for treatment, clinically significant pericardial disease, cardiac amyloidosis, transient ischemic attacks, CVA, coronary artery or other vascular stents).
Unstable cardiovascular function:\r\n* Electrocardiogram (ECG) abnormalities requiring treatment, or\r\n* Congestive heart failure (CHF) of New York Heart Association (NYHA) class >= \r\n* Myocardial infarction (MI) within  months
History of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of , unstable angina or poorly controlled arrhythmia, or myocardial infarction within  months
Significant cardiovascular disease (i.e. New York Heart Association [NYHA] class  congestive heart failure; myocardial infarction with the past  months; unstable angina; coronary angioplasty with the past  months; uncontrolled atrial or ventricular cardiac arrhythmias)
. Uncontrolled or severe cardiovascular disease, including myocardial infarct or unstable angina within  months prior to study treatment, New York Heart Association Class II or greater congestive heart failure, serious arrhythmias requiring medication for treatment, clinically significant pericardial disease, or cardiac amyloidosis.
Clinically significant (that is [i.e.] active) cardiovascular disease (For example [e.g.] cerebrovascular accident or myocardial infarction within  months prior to randomization), unstable angina, congestive heart failure (New York Heart Association Class >/= II) or serious cardiac arrhythmia that is uncontrolled by medication or may interfere with the administration of the study treatment
Patients with uncontrolled hypertension (> /), unstable coronary disease evidenced by uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure (CHF) (> New York Heart Association [NYHA] class II), or myocardial infarction within  months of study will be excluded
Clinically significant cardiovascular disease (eg, uncontrolled hypertension, myocardial infarction, unstable angina), New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication within  year prior to Day - (Visit ); Grade II or greater peripheral vascular disease at study entry
Myocardial infarction, unstable angina within the past  months, or congestive heart failure New York Heart Association Class II or greater
Symptomatic congestive heart failure (New York Heart Association Classification > Class II), unstable angina, or unstable cardiac arrhythmia requiring medication
Myocardial infarction, symptomatic congestive heart failure (New York Heart Association Classification > Class II), unstable angina, or serious uncontrolled cardiac arrhythmia within the last  months of study Day 
Unstable cardiovascular function:\r\n* Electrocardiogram (ECG) abnormalities requiring treatment, or\r\n* Congestive heart failure (CHF) of New York Heart Association (NYHA) class >= \r\n* Myocardial infarction (MI) within  months\r\n* Symptomatic ischemia or angina
New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF); myocardial infarction or unstable angina within  months
History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of , unstable angina or poorly controlled arrhythmia; myocardial infarction within  months prior to randomization
Patients with clinically significant cardiovascular disease (eg, significant cardiac conduction abnormalities, uncontrolled hypertension, myocardial infarction, cardiac arrhythmia or unstable angina <  months to enrollment, New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, Grade II or greater peripheral vascular disease, and history of cerebrovascular accident (CVA) within  months).
Significant cardiovascular impairment: congestive heart failure > class II according to the New York Heart Association (NYHA), unstable angina or myocardial infarction within  months of enrollment, or serious cardiac arrhythmia (> grade )
Myocardial infarction within  months of study day , symptomatic congestive heart failure (New York Heart Association > class II), unstable angina, or unstable cardiac arrhythmia requiring medication, or uncontrolled hypertension in the opinion of the investigator
Unstable angina, myocardial infarction, cerebrovascular accident, >= Class II congestive heart failure according to the New York Heart Association Classification for Congestive Heart Failure within  months before enrollment.
Myocardial infarction within  months of study day , symptomatic congestive heart failure (New York Heart Association > class II), unstable angina, or unstable cardiac arrhythmia requiring medication, or uncontrolled hypertension
Clinically significant cardiovascular disease (e.g., hypertension [blood pressure [BP] > /], myocardial infarction or stroke within  months, unstable angina), New York Heart Association (NYHA) grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication
Patients with uncontrolled hypertension (> /), unstable coronary disease evidenced by uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure (CHF) (> New York Heart Association [NYHA] class II), or myocardial infarction within  months of study will be excluded
Uncontrolled or severe cardiovascular disease, including myocardial infarct or unstable angina within  months prior to study treatment, New York Heart Association (NYHA) class II or greater congestive heart failure, serious arrhythmias requiring medication for treatment, clinically significant pericardial disease or cardiac amyloidosis
Unstable cardiovascular function:\r\n* Electrocardiography (ECG) abnormalities requiring treatment, or\r\n* Congestive heart failure (CHF) of New York Heart Association (NYHA) class >= \r\n* Myocardial infarction (MI) within  months
Unstable cardiovascular function:\r\n* Symptomatic ischemia\r\n* Congestive heart failure New York Heart Association (NYHA) class > \r\n* Myocardial infarction (MI) within  months
Significant cardiovascular impairment: history of (a) congestive heart failure greater than New York Heart Association (NYHA) Class II; (b) unstable angina; (c) myocardial infarction; (d) stroke; or (e) cardiac arrhythmia associated with hemodynamic instability within  months of the first dose of study drugs
Patient has uncontrolled angina, congestive heart failure (New York Heart Association > class II or known ejection fraction < %), uncontrolled cardiac arrhythmia or hypertension, or acute myocardial infarction within  months
Patient has uncontrolled angina, congestive heart failure (New York Heart Association > class II or known ejection fraction < %), uncontrolled cardiac arrhythmia or hypertension, or acute myocardial infarction within  months
Significant cardiovascular disease, such as New York Heart Association (NYHA) cardiac disease (Class II or greater), myocardial infarction within  months prior to Day , unstable arrhythmias, or unstable angina
History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of , unstable angina or poorly controlled arrhythmia, myocardial infarction within  months prior to study entry
New York Heart Association congestive heart failure of grade II or above, unstable angina, myocardial infarction within the past  months, or serious cardiac arrhythmia associated with significant cardiovascular impairment within the past  months; ejection fraction (EF) by multi-gated acquisition (MUGA) or echo should not be less than the institutional lower limit of normal
Myocardial infarction within  months before starting therapy, symptomatic congestive heart failure (New York Heart Association > class II), unstable angina, or unstable cardiac arrhythmia requiring medication
Myocardial infarction within  months before starting therapy, symptomatic congestive heart failure (New York Heart Association > class II), unstable angina, or unstable cardiac arrhythmia requiring medication
Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or cerebral vascular accident within  months of the first dose of study drug, or cardiac arrhythmia associated with hemodynamic instability.
